Personalis, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
PSNL$15.88-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
(a) Financial Statements and Schedules
The financial statements are set forth under Item 8 of this Annual Report on Form 10-K, as indexed below. Financial statement schedules have been omitted since they either are not required, not applicable, or the information is otherwise included.
| INDEX TO CONSOLIDATED FINANCIAL STATEMENTS | |
|---|---|
| Page | |
| Consolidated Balance Sheets | 70 |
| Consolidated Statements of Operations | 71 |
| Consolidated Statements of Comprehensive Loss | 72 |
| Consolidated Statements of Stockholders’ Equity | 73 |
| Consolidated Statements of Cash Flows | 74 |
| Notes to Consolidated Financial Statements | 75 |
| Report of Independent Registered Public Accounting Firm | 97 |
(b) Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-38943 | 3.1 | 6/24/2019 |
| 3.2* | Amended and Restated Bylaws of the Registrant. | ||||
| 4.1 | Description of Securities of Personalis, Inc. | 10-K | 001-38943 | 4.1 | 2/25/2021 |
| 4.2 | Form of Common Stock Certificate of the Registrant. | S-1/A | 333-231703 | 4.1 | 6/7/2019 |
| 4.3 | Investment Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc. | 8-K | 001-38943 | 4.1 | 8/16/2024 |
| 4.4 | Investment Agreement, dated December 19, 2024, by and between the Registrant and Merck Sharp & Dohme LLC. | 8-K | 001-38943 | 4.1 | 12/19/2024 |
| 10.1# | Personalis, Inc. 2011 Equity Incentive Plan, as amended, and forms of agreements thereunder. | S-1 | 333-231703 | 10.1 | 5/23/2019 |
| 10.2# | Personalis, Inc. 2019 Equity Incentive Plan and forms of agreements thereunder. | S-1/A | 333-231703 | 10.2 | 6/7/2019 |
| 10.3# | Personalis, Inc. 2019 Employee Stock Purchase Plan. | S-1/A | 333-231703 | 10.3 | 6/7/2019 |
| 10.4*# | Personalis, Inc. 2020 Inducement Plan, as amended. | ||||
| 10.5# | Form of RSU Award Agreement under 2020 Inducement Plan. | 10-K | 001-38943 | 10.5 | 2/28/2024 |
| 10.6# | Form of Option Agreement under 2020 Inducement Plan. | 10-K | 001-38943 | 10.6 | 2/28/2024 |
| 10.7# | Form of Indemnification Agreement entered into by and between the Registrant and each director and executive officer. | S-1/A | 333-231703 | 10.4 | 6/7/2019 |
| 10.8# | Amended and Restated Non-Employee Director Compensation Policy, dated February 27, 2024 | 10-Q | 001-38943 | 10.1 | 5/8/2024 |
| 10.9# | Amended and Restated Employment Agreement dated March 7, 2023, between the Registrant and Aaron Tachibana. | 8-K | 001-38943 | 10.1 | 3/8/2023 |
| 10.10# | Amended and Restated Offer Letter, dated March 7, 2023, between the Registrant and Christopher Hall. | 8-K | 001-38943 | 10.2 | 3/8/2023 |
| 10.11# | Amended and Restated Employment Agreement dated March 8, 2023, between the Registrant and Richard Chen. | 8-K | 001-38943 | 10.3 | 3/8/2023 |
| 10.12# | Second Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Christopher Hall. | 10-K | 001-38943 | 10.12 | 2/28/2024 |
| 10.13# | Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Aaron Tachibana. | 10-K | 001-38943 | 10.13 | 2/28/2024 |
| 10.14# | Third Amended and Restated Executive Severance Agreement, dated September 25, 2023, between the Registrant and Richard Chen. | 10-K | 001-38943 | 10.14 | 2/28/2024 |
| 10.15# | Second Amended and Restated Executive Severance Agreement, dated September 18, 2023, between the Registrant and Stephen Moore. | 10-K | 001-38943 | 10.15 | 2/28/2024 |
| 10.16Ω‡ | Commercialization and Reference Laboratory Agreement, between the Registrant and Tempus AI, Inc., dated November 25, 2023. | 8-K | 001-38943 | 10.1 | 11/28/2023 |
| 10.17Ω‡ | Amendment No. 1 to the Commercialization and Reference Laboratory Agreement, dated August 16, 2024, by and between the Registrant and Tempus AI, Inc. | 8-K | 001-38943 | 10.1 | 8/16/2024 |
| 10.18 | Amendment No. 2 to the Commercialization and Reference Laboratory Agreement, dated September 20, 2024, by and between the Registrant and Tempus AI, Inc. | 10-Q | 001-38943 | 10.2 | 11/6/2024 |
| 10.19Ω | Amendment No. 3 to the Commercialization and Reference Laboratory Agreement, dated December 13, 2024, by and between the Registrant and Tempus AI, Inc. | 10-K | 001-38943 | 10.19 | 2/27/2025 |
| 10.20 | Lease, by and between MENLO PREHC I, LLC, MENLO PREPI I, LLC, TPI INVESTORS 9, LLC and the Registrant, dated February 2, 2015. | S-1 | 333-231703 | 10.9 | 5/23/2019 |
| 10.21 | First Amendment to Lease, by and between MENLO PREPI I, LLC and TPI INVESTORS 9, LLC and the Registrant, dated April 8, 2020. | 10-Q | 001-38943 | 10.1 | 8/6/2020 |
| 10.22 | Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated August 25, 2021. | 10-Q | 001-38943 | 10.1 | 11/4/2021 |
| 10.23 | Amendment No. 1 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 8, 2021. | 10-K | 001-38943 | 10.16 | 2/24/2022 |
| 10.24 | Amendment No. 2 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated June 9, 2022. | 10-Q | 001-38943 | 10.1 | 8/3/2022 |
| 10.25 | Amendment No. 3 to Lease, by and between Ardenwood Ventures I, LLC and the Registrant, dated December 19, 2022. | 10-K | 001-38943 | 10.19 | 2/23/2023 |
| 10.26‡ | Contract No. 36C24E22D0031, by and between the U.S. Department of Veterans Affairs and the Registrant, dated September 30, 2022. | 10-Q | 001-38943 | 10.1 | 11/2/2022 |
| 10.27Ω | Amendment No. 4 to the Commercialization and Reference Laboratory Agreement, dated July 8, 2025, by and between the Registrant and Tempus AI, Inc. | 10-Q | 001-38943 | 10.1 | 11/4/2025 |
| 10.28 | Amendment No. 5 to the Commercialization and Reference Laboratory Agreement, dated September 11, 2025, by and between the Registrant and Tempus AI, Inc. | 10-Q | 001-38943 | 10.2 | 11/4/2025 |
| 10.29 | Amended and Restated At-the-Market Sales Agreement, dated December 27, 2024, by and among the Registrant, Piper Sandler & Co. and BTIG, LLC. | 8-K | 001-38943 | 1.1 | 12/27/2024 |
| 10.30Ω‡ | Settlement and License Agreement, between the Registrant. and Foresight Diagnostics, Inc., dated June 21, 2024. | 10-Q | 001-38943 | 10.1 | 8/7/2024 |
| 19.1* | Insider Trading Policy. | ||||
| 21.1* | Subsidiaries of the Registrant as of December 31, 2025. | ||||
| 23.1* | Consent of Independent Registered Public Accounting Firm. | ||||
| 24.1* | Power of Attorney (included on the Signatures page of this Annual Report on Form 10-K). | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*† | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2*† | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97# | Incentive Compensation Recoupment Policy. | 10-K | 001-38943 | 97 | 2/28/2024 |
| 101* | Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. | ||||
| 104* | Inline XBRL for the cover page of this Annual Report on Form 10-K, included in the Exhibit 101 Inline XBRL Document Set. | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.